Monte Rosa Therapeutics (GLUE) News Today → 4 Cryptos BETTER than Bitcoin (From True Market Insiders) (Ad) Free GLUE Stock Alerts $5.20 -0.02 (-0.38%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 7:00 AM | globenewswire.comMonte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public OfferingMay 15 at 4:01 PM | globenewswire.comMonte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Monte Rosa Therapeutics Amidst Promising Drug Pipeline and Stable FinancialsMay 10, 2024 | finance.yahoo.comMonte Rosa Therapeutics Reports Q1 2024 Financial Results: A Detailed OverviewMay 9, 2024 | investorplace.comGLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | globenewswire.comMonte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 4, 2024 | finanznachrichten.deMonte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific OfficerMay 2, 2024 | finance.yahoo.comMonte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific OfficerMay 2, 2024 | globenewswire.comMonte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific OfficerMay 1, 2024 | marketbeat.comShort Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Increases By 11.3%Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 1,870,000 shares, a growth of 11.3% from the March 31st total of 1,680,000 shares. Based on an average daily volume of 131,800 shares, the days-to-cover ratio is presently 14.2 days. Currently, 5.9% of the shares of the stock are sold short.April 16, 2024 | marketbeat.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest UpdateMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 1,680,000 shares, a drop of 8.2% from the March 15th total of 1,830,000 shares. Based on an average trading volume of 150,300 shares, the days-to-cover ratio is currently 11.2 days. Currently, 5.3% of the shares of the company are sold short.March 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)March 19, 2024 | marketbeat.comShort Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Decreases By 7.1%Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the target of a significant decline in short interest during the month of February. As of February 29th, there was short interest totalling 1,840,000 shares, a decline of 7.1% from the February 14th total of 1,980,000 shares. Based on an average daily volume of 191,000 shares, the short-interest ratio is currently 9.6 days. Approximately 5.8% of the company's shares are sold short.March 19, 2024 | finance.yahoo.comWall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should KnowMarch 16, 2024 | finance.yahoo.comMonte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial ResultsMarch 15, 2024 | finance.yahoo.comIs Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?March 14, 2024 | markets.businessinsider.comPromising Clinical Progress and Strategic Milestones Bolster Buy Rating for Monte Rosa TherapeuticsMarch 14, 2024 | investorplace.comGLUE Stock Earnings: Monte Rosa Therapeutics Misses EPS for Q4 2023March 14, 2024 | finanznachrichten.deMonte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 14, 2024 | benzinga.comMonte Rosa Therapeutics: Q4 Earnings InsightsMarch 14, 2024 | globenewswire.comMonte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 11, 2024 | globenewswire.comMonte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway InhibitorMarch 4, 2024 | marketbeat.comFmr LLC Sells 540,899 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)Fmr LLC trimmed its holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) by 8.3% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 6,004,833 shares of the company's stock after selling 540,899 shares during the quarter. Fmr LLCMarch 1, 2024 | morningstar.comMonte Rosa Therapeutics Inc GLUEFebruary 24, 2024 | msn.comMonte Rosa Therapeutics (GLUE) Price Target Increased by 5.66% to 16.32February 23, 2024 | benzinga.comMonte Rosa Therapeutics Stock (NASDAQ:GLUE), Analyst Ratings, Price Targets, PredictionsFebruary 15, 2024 | msn.comMonte Rosa draws bullish view at Wedbush on protein degradationFebruary 15, 2024 | msn.comMonte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: AnalystFebruary 15, 2024 | marketbeat.comMonte Rosa Therapeutics (NASDAQ:GLUE) Coverage Initiated by Analysts at WedbushWedbush assumed coverage on shares of Monte Rosa Therapeutics in a report on Thursday. They set an "outperform" rating and a $11.00 target price on the stock.February 13, 2024 | marketbeat.comMonte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 4.3%Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 4.3%January 16, 2024 | fool.com3 Incredible Growth Stocks That Could Soar in 2024, According to Wall StreetJanuary 8, 2024 | finance.yahoo.comMonte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024January 3, 2024 | finance.yahoo.comMonte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 31, 2023 | marketbeat.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Significant Decline in Short InterestMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the target of a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 2,360,000 shares, a decline of 20.5% from the November 30th total of 2,970,000 shares. Approximately 7.5% of the company's shares are sold short. Based on an average daily volume of 305,200 shares, the short-interest ratio is presently 7.7 days.December 4, 2023 | benzinga.comMonte Rosa Therapeutics Stock (NASDAQ:GLUE) Earnings Dates and Earning CallsDecember 4, 2023 | benzinga.comMonte Rosa Therapeutics Stock (NASDAQ:GLUE) Dividends: History, Yield and DatesNovember 21, 2023 | finance.yahoo.comMonte Rosa Therapeutics to Present at Piper Sandler Healthcare ConferenceNovember 14, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Celldex (CLDX), Monte Rosa Therapeutics (GLUE) and Solid Biosciences (SLDB)November 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Vertex (VERX) and Monte Rosa Therapeutics (GLUE)November 9, 2023 | benzinga.comMonte Rosa Therapeutics: Q3 Earnings InsightsNovember 9, 2023 | finance.yahoo.comMonte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 9, 2023 | finance.yahoo.comMonte Rosa Therapeutics Inc (GLUE) Reports Q3 2023 Financial Results and Strategic DevelopmentsNovember 7, 2023 | finance.yahoo.comMonte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory DiseasesOctober 31, 2023 | nasdaq.comMonte Rosa Therapeutics, Inc. Common Stock (GLUE)October 31, 2023 | msn.comMonte Rosa Therapeutics: Roche Partnership Deal Could Bring Added ValueOctober 30, 2023 | marketwatch.comMonte Rosa Therapeutics Shares Rise for Second Session in a RowOctober 26, 2023 | msn.comMonte Rosa Therapeutics prices offering to raise $25MOctober 26, 2023 | finance.yahoo.comMonte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq RulesOctober 24, 2023 | finance.yahoo.comDown -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE)October 20, 2023 | msn.comJP Morgan Maintains Monte Rosa Therapeutics (GLUE) Overweight Recommendation Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address 4 Cryptos BETTER than Bitcoin (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin Click For My #1 FREE Crypto for 2024 GLUE Media Mentions By Week GLUE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLUE News Sentiment▼0.760.51▲Average Medical News Sentiment GLUE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLUE Articles This Week▼21▲GLUE Articles Average Week Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MGX News STRO News CHRS News PSTX News AGEN News ZURA News CMPX News ABOS News ADAP News IVVD News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLUE) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaObama’s Forever Term [exposed]Porter & CompanyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryMost important medical advance in 100 yearsThe Oxford ClubBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
